Blog

Giulio Francolini: QoL data from DART trial

Giulio Francolini/urotoday.com

May 4, 2025, 12:33

Giulio Francolini: QoL data from DART trial

Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:

“QoL data from DART trial (SBRT+/- darolutamide in oligorec. pCa).

Global health and most QoL subdomains remained stable in both arms over the 24-week period.

More fatigue and hormonal treatment-related symptoms were observed in the SBRT and DARO arm, ESTRO.”

The post presents updated findings from the DART trial, indicating stable quality of life across both study arms over 24 weeks.

However, patients receiving both SBRT and darolutamide experienced increased fatigue and hormonal symptoms.

Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.

cancer Careggi University Hospital darolutamide DART trial ESTRO fight against cancer Giulio Francolini Global fight against cancer global health OncoDaily Oncology QoL data Radiation Oncologist SBRT

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology